



## Advances in Immunotherapy and Radiation Therapy for Cancer

Guest Editors:

**Dr. Ivaylo B. Mihaylov**

Department of Radiation  
Oncology, Miller School of  
Medicine, Sylvester  
Comprehensive Cancer Center,  
University of Miami, Miami, FL  
33136, USA

**Dr. Benjamin Spieler**

Department of Radiation  
Oncology, Leonard M. Miller  
School of Medicine, University of  
Miami, 1475 NW 12th Ave., Suite  
1500, Miami, FL 33136, USA

Deadline for manuscript  
submissions:

**30 June 2024**

### Message from the Guest Editors

The goal of this Special Issue is to publish innovative research related to immunotherapy combined with radiotherapy for cancer treatment. The inclusion of additional treatment modalities, such as chemotherapy, targeted therapy, hyperthermia, etc., is also of interest. The Special Issue is open to both clinical and preclinical studies, and to different disease sites and cancer types. The clinical studies should also encompass a preclinical component in order to be considered. The clinical component of interest is the impact of therapeutics on meaningful endpoints such as progression-free and overall survival. In the preclinical setting, improving the synergy of combination therapeutics through the optimization of sequencing, dosing, timing, and fractionation is of particular interest. Both mechanistic and phenomenological studies will be considered. Submissions may be related either to tumor control/response or to normal tissue side effects resulting from treatment. Predictive modeling intended to support clinical decision-making and pertinent to disease response or normal tissue complications is an additional area of interest.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Felipe Fregni

1. Neuromodulation Center and  
Center for Clinical Research

Learning, Spaulding  
Rehabilitation Hospital and  
Massachusetts General Hospital,  
Harvard Medical School, Boston,  
MA 02114, USA

2. Department of Epidemiology,  
Harvard T.H. Chan School of  
Public Health, Boston, MA 02115,  
USA

## Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

## Author Benefits

**Open Access:** free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

**High Visibility:** indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

**Journal Rank:** JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

## Contact Us

*Biomedicines* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/biomedicines](http://mdpi.com/journal/biomedicines)  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)  
[X@Biomed\\_MDPI](#)